Aquaporin-4 and Alzheimer's Disease

被引:46
|
作者
Yang, Canhong [1 ]
Huang, Xiaomin [1 ]
Huang, Xiaoyu [1 ]
Mai, Hantao [1 ]
Li, Jie [1 ]
Jiang, Tao [1 ]
Wang, Xiaofeng [1 ]
Lu, Tianming [1 ]
机构
[1] Southern Med Univ, Affiliated Hosp 3, Dept Neurol, 183 Zhongshan Rd West, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; amyloid-beta protein; aquaporin-4; astrocyte; cerebral amyloid angiopathy; synaptic function; CEREBRAL AMYLOID ANGIOPATHY; BLOOD-BRAIN-BARRIER; MORRIS WATER MAZE; A-BETA; THERAPEUTIC IMPLICATIONS; CEREBROSPINAL-FLUID; TRANSGENIC MICE; NERVOUS-SYSTEM; SENILE PLAQUES; SPATIAL MEMORY;
D O I
10.3233/JAD-150949
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease (AD) is the most common form of dementia. Although the pathogenesis of AD remains unclear, AD is thought to result from an imbalance in the production and clearance of amyloid-beta protein (A beta). Aquaporin-4 (AQP4) is the major aquaporin in the mammalian brain, is mostly expressed on astrocytic endfeet, and functions as a water transporter. However, the distribution and expression of AQP4 are altered in both AD clinical populations and animal models. Recent studies have revealed that AQP4 is important to the clearance of A beta in brain via lymphatic clearance, transcytotic delivery, and glial degradation, as well as to the synaptic function. Thus, AQP4 likely plays an important role in the pathogenesis of AD. Further studies would provide new targets for prevention, ultimately leading to improved treatment options for AD.
引用
收藏
页码:391 / 402
页数:12
相关论文
共 50 条
  • [21] Aquaporin-4 reduces neuropathology in a mouse model of Alzheimer’s disease by remodeling peri-plaque astrocyte structure
    Alex J. Smith
    Tianjiao Duan
    Alan S. Verkman
    Acta Neuropathologica Communications, 7
  • [22] Aquaporin-4 autoimmunity
    Zekeridou, Anastasia
    Lennon, Vanda A.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (04):
  • [23] Aquaporin-4 autoimmunity
    Misu, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S20 - S21
  • [24] Aquaporin-4 and epilepsy
    Binder, Devin K.
    Nagelhus, Erlend A.
    Ottersen, Ole Petter
    GLIA, 2012, 60 (08) : 1203 - 1214
  • [25] Investigating the Role of Aquaporin-4 Mediated Glymphatic Clearance in Parkinson's Disease
    Llewellyn, Sophie K.
    Lopes, Douglas M.
    Gentleman, Steve M.
    Schapira, Anthony H. V.
    Lythgoe, Mark F.
    Harrison, Ian F.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2025, 51
  • [26] Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica
    Sven Jarius
    Friedemann Paul
    Diego Franciotta
    Patrick Waters
    Frauke Zipp
    Reinhard Hohlfeld
    Angela Vincent
    Brigitte Wildemann
    Nature Clinical Practice Neurology, 2008, 4 : 202 - 214
  • [27] Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica
    Jarius, Sven
    Paul, Friedemann
    Franciotta, Diego
    Waters, Patrick
    Zipp, Frauke
    Hohlfeld, Reinhard
    Vincent, Angela
    Wildemann, Brigitte
    NATURE CLINICAL PRACTICE NEUROLOGY, 2008, 4 (04): : 202 - 214
  • [28] The role of aquaporin-4 in synaptic plasticity, memory and disease
    Hubbard, Jacqueline A.
    Szu, Jenny I.
    Binder, Devin K.
    BRAIN RESEARCH BULLETIN, 2018, 136 : 118 - 129
  • [29] A "glympse" into neurodegeneration: Diffusion MRI and cerebrospinal fluid aquaporin-4 for the assessment of glymphatic system in Alzheimer's disease and other dementias
    Sacchi, Luca
    D'Agata, Federico
    Campisi, Corrado
    Arcaro, Marina
    Carandini, Tiziana
    Orzsik, Balazs
    Dal Maschio, Vera Pacoova
    Fenoglio, Chiara
    Pietroboni, Anna Margherita
    Ghezzi, Laura
    Serpente, Maria
    Pintus, Manuela
    Conte, Giorgio
    Triulzi, Fabio
    Lopiano, Leonardo
    Galimberti, Daniela
    Cercignani, Mara
    Bozzali, Marco
    Arighi, Andrea
    HUMAN BRAIN MAPPING, 2024, 45 (12)
  • [30] Aquaporin 4 in Astrocytes is a Target for Therapy in Alzheimer's Disease
    Lan, Yu-Long
    Chen, Jian-Jiao
    Hu, Gang
    Xu, Jun
    Xiao, Ming
    Li, Shao
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (33) : 4948 - 4957